Oncolytics Biotech, Inc. (NASDAQ:ONCY) has earned an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company. Oncolytics Biotech’s rating score has declined by 50% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 12 month consensus price objective of $13.62 for the company, according to Zacks. Zacks has also given Oncolytics Biotech an industry rank of 51 out of 256 based on the ratings given to related companies.
ONCY has been the subject of several analyst reports. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.
Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.21) EPS for the quarter. On average, equities analysts expect that Oncolytics Biotech will post -0.9 EPS for the current fiscal year.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Read More: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.